The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial.
 
Monika Karla Graeser
Consulting or Advisory Role - AstraZeneca
Travel, Accommodations, Expenses - Daiichi Sankyo/Astra Zeneca
 
Oleg Gluz
Honoraria - AstraZeneca; Celgene; Genomic Health; Lilly; MSD; NanoString Technologies; Novartis; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Amgen; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; Merck Sharp & Dohme; MolecularHealth; Pfizer; Pierre Fabre; Roche; Seagen
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
 
Ulrike Nitz
Honoraria - Agendia; Amgen; Celgene; Genomic Health; NanoString Technologies; Novartis; Pfizer; Roche; Teva
Consulting or Advisory Role - Genomic Health; Roche; Seagen
Research Funding - Agendia (Inst); Amgen (Inst); Celgene (Inst); Genomic Health (Inst); NanoString Technologies (Inst); Roche (Inst); Sanofi (Inst)
Expert Testimony - Genomic Health
Travel, Accommodations, Expenses - Genomic Health; Pfizer; Roche
 
Claudia Biehl
No Relationships to Disclose
 
Angela Berg
No Relationships to Disclose
 
Matthias Christgen
No Relationships to Disclose
 
Sherko Kuemmel
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Celgene; Daiichi Sankyo; Genomic Health; Gilead Sciences; Lilly; MSD Oncology; Novartis; Pfizer; pfm medical; Roche/Genentech; Seagen; SOMATEX; Sonoscape
Travel, Accommodations, Expenses - Daiichi Sankyo; Gilead Sciences; Roche
(OPTIONAL) Uncompensated Relationships - West German Study Group
 
Johannes Holtschmidt
Honoraria - Novartis; Roche; Seagen
Consulting or Advisory Role - Daiichi Sankyo; MSD; Novartis; Palleos; Pfizer; Tesaro
Research Funding - Hologic
 
Johannes Schumacher
Employment - Palleos
 
Andreas D. Hartkopf
Honoraria - Agendia; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo Pharmaceutical; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly O.; MSD; Novartis; Onkowissen; Pfizer; Pierre Fabre; Roche; Seagen
Consulting or Advisory Role - Agendia; Amgen; AstraZeneca; Clovis Oncology; Daiichi Sankyo Pharmaceutical; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly O.; MSD; Novartis; Onkowissen; Pfizer; Pierre Fabre; Roche; Seagen
Speakers' Bureau - AstraZeneca; Eisai; Exact Sciences; Gilead Sciences; GlaxoSmithKline; Lilly O.; MSD; Novartis; Pfizer; Roche; Seagen
Research Funding - Exact Sciences
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Pfizer; Roche
 
Jochem Potenberg
No Relationships to Disclose
 
Kerstin Luedtke-Heckenkamp
No Relationships to Disclose
 
Marianne Just
No Relationships to Disclose
 
Christian Schem
No Relationships to Disclose
 
Christine zu Eulenburg
Honoraria - Lilly
Consulting or Advisory Role - HMNC Brain Health
 
Timo Schinkoethe
Employment - CANKADO
Leadership - CANKADO
Stock and Other Ownership Interests - CANKADO
Honoraria - Amgen (I); Baxter (I); Boehringer Ingelheim (I); Bristol-Myers Squibb (I); Celgene (I); Ipsen (I); Merck (I); MSD (I); Novartis (I); Pfizer (I); Pierre Fabre (I); Roche (I); Takeda (I)
 
Rachel Wuerstlein
Consulting or Advisory Role - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo Pharmaceutical; Eisai; Exact Sciences; Genomic Health; Genzyme; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly O.; Medstorm Medical; MSD; Mundipharma; Mylan; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz; Sanofi; Seagen; Tesaro; Teva; Veracyte; Viatris
Speakers' Bureau - Agendia; Amgen; Aristo; AstraZeneca; Boehringer Ingelheim; Carl Zeiss Meditec; Celgene; Daiichi Sankyo Pharmaceutical; Eisai; Exact Sciences; Genomic Health; Gilead Sciences; GlaxoSmithKline; Hexal; Lilly O.; Medstrom Medical; MSD; Mundipharma; Mylan; NanoString Technologies; Novartis; Odonate Therapeutics; Palleos; Paxman; Pfizer; Pierre Fabre; Puma Biotechnology; RIEMSER; Roche; Sandoz; Sanofi; Seagen; Tesaro; Teva; Veracyte; Viatris
 
Ronald E. Kates
Honoraria - Amgen (I); Celgene (I); Genomic Health (I); NanoString Technologies (I); Novartis (I); Pfizer (I); Roche (I)
Consulting or Advisory Role - Agendia (I); AstraZeneca (I); Celgene (I); Daiichi Sankyo (I); Lilly (I); Merck Sharp & Dohme (I); Novartis (I); Odonate Therapeutics (I); Pfizer (I); Roche/Genentech (I); Sandoz (I); Seagen (I)
 
Hans Heinrich Kreipe
No Relationships to Disclose
 
Nadia Harbeck
Stock and Other Ownership Interests - West German Study Group
Honoraria - Amgen; AstraZeneca; Daiichi-Sankyo; Gilead Sciences; Lilly; MSD; Novartis; Pfizer; Pierre Fabre; Roche; Sanofi; Seagen; Viatris; Zuelligpharma
Consulting or Advisory Role - Gilead Sciences; Novartis; Roche/Genentech; Sandoz; Seagen; West German Study Group (I)
Speakers' Bureau - EPG Communication; Medscape; Springer Healthcare
Research Funding - AstraZeneca (Inst); Lilly (Inst); MSD (Inst); Roche/Genentech (Inst)